Coherus BioSciences
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
Phone: 800-794-5434Website: https://www.coherus.com/Careers: www.coherus.com/join-our-team
Latest news
- Coherus Announces FDA Approval of Udenyca Onbody™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
26 December 2023 - FDA Approves Loqtorzi (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
27 October 2023 - Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for Udenyca ® OnBody™
5 October 2023 - Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
5 June 2023 - Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
15 February 2023 - Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
24 December 2022 - Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
12 October 2022 - FDA Approves Cimerli (ranibizumab-eqrn), an Interchangeable Biosimilar to Lucentis
2 August 2022 - Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
6 July 2022 - Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
2 May 2022
Drugs Associated with Coherus BioSciences, Inc.
Coherus BioSciences, Inc. manufactures, markets and/or distributes more than 4 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Cimerli
Generic name: ranibizumab Drug class: anti-angiogenic ophthalmic agents |
||
|
Loqtorzi
Generic name: toripalimab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) |
||
|
Udenyca
Generic name: pegfilgrastim Drug class: colony stimulating factors |
3 reviews | 1.0 / 10 |
|
Yusimry
Generic name: adalimumab Drug class: TNF alfa inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
